Search Results 191-200 of 15547 for TNF

  1. Efficacy and Safety of Vedolizumab Subcutaneous (SC) as Maintenance Therapy in Crohn's Disease - Mayo Clinic

    Inadequate response with, loss of response to, or intolerance to corticosteroids, immunomodulators, or Tumor necrosis factor-alpha (TNF-α) antagonists.

  2. JavaScript is disabled. In order to continue, we need to verify that you're not a robot. This requires JavaScript. Enable JavaScript and then reload the page.

  3. Stem Cell Fistula Plug in Perianal Crohn's Disease - Mayo Clinic

    Concurrent therapies with corticosteroids, 5-ASA drugs, thiopurines, MTX, antibiotics, and anti-TNF therapy are permitted. All patients should have ...

  4. Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD) - Mayo Clinic

    Demonstrated intolerance or inadequate response to one or more anti-tumor necrosis factor (TNF) therapies. Exclusion Criteria: Current diagnosis of ...

  5. vasculitis Archives - Mayo Clinic News Network

    ... tumor necrosis factor inhibitors, part of a class of drugs called biologics. It comes down to proteins: specifically, a protein in the body that drives ...

  6. Randomized Study of Topical Alicaforsen Enema in Antibiotic Refractory Pouchitis - Mayo Clinic

    Biological agents: Anti-tumour necrosis factor (anti - TNF) therapy and / or vedolizumab; are not permitted within 8 weeks of the Screening Visit. All other ...

  7. A Study of the Use of a New Drug in People with Non-Alcoholic Steatohepatitis (NASH) or Non-Alcoholic Fatty Liver Disease (NAFLD) - Mayo Clinic

    Additionally, if subjects are taking drugs such Vit E, Ursodeoxycholic acid, Gemfibrozil, anti TNF therapies and probiotics will be allowed if on stable ...

  8. Evaluation of CRS-207 With Pembrolizumab in Previously Treated MPM - Mayo Clinic

    Receiving TNF pathway inhibitors, PI3 kinase inhibitors, systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the ...

  9. A Study to Assess the Effectiveness and Safety of Golimumab in Pediatric Participants With Moderately-to-Severely Active Ulcerative Colitis - Mayo Clinic

    Contraindications to the use of golimumab or infliximab or anti-tumor necrosis factor (TNF-alpha) therapy per local prescribing information. Participating ...

  10. CAST-AI: Cystectomy after systemic therapy with ADC and Immunotherapy - Mayo Clinic

    ... tumor necrosis factor (TNF) or anti-interleukin (IL)-6 agents are excluded * Participants still recovering from toxicity of prior anticancer therapy which ...